{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:08:44Z","timestamp":1789668524631,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to identify the incidence of clinical understaging in early gastric cancer (GC) and to identify variables associated with increased risk of a patient being understaged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical stage I (T1\/2 N0) GC patients undergoing oncologic resection without neoadjuvant therapy from 2013 to 2020 were identified in the National Cancer Database (NCDB). Patients found to have a higher stage of cancer on final pathologic review were considered understaged. Clinicopathologic predictors of understaging were identified using multivariable logistic regression. The relationship between identified variables and understaging was modeled using logistic regression with natural cubic splines to allow for a flexible, nonlinear analysis. Cox proportional hazards analysis and Kaplan-Meier curves were used to evaluate survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study identified 4370 clinical stage I GC patients, 36% of whom were initially understaged on clinical staging. Tumor size per millimeter increase (OR, 1.05; 95% confidence interval CI 1.04\u20131.05;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), higher grade (moderate: OR, 2.76; 95% CI 1.99\u20133.84; poor\/anaplastic status: OR, 5.99; 95% CI 1.99\u20133.84,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and non-academic treatment facilities (OR, 1.19; 95% CI 1.03\u20131.38;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.017) were associated with increased risk of understaging. Spline analysis showed increased risk of understaging based on tumor size. This was compounded when tumor differentiation was considered, such that a tumor measuring 2.5\u00a0cm was associated with 16.9%, 31.8%, or 51.6% likelihood of clinical understaging if the tumor was well, moderately, or poorly differentiated, respectively. Understaging was associated with increased mortality (OR, 2.31; 95% CI 2.10\u20132.95;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than one third of clinical stage I GC patients are understaged. Tumor grade and size should be considered at preoperative evaluation of early GC to improve identification of patients at risk for understaging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19973-8","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:49:58Z","timestamp":1784040598000},"page":"9257-9267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High Prevalence of Clinical Understaging in Early Gastric Cancer: An Analysis of the NCDB"],"prefix":"10.1245","volume":"33","author":[{"given":"Alexandra","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"De La Torre Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayavadhan","family":"Thuppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam F.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Ecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miral Sadaria","family":"Grandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Handorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haejin","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"19973_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin."},{"key":"19973_CR2","unstructured":"National Institutes of Health\u2013National Cancer Institute: SEER. Cancer Stat Facts: Stomach Cancer. Retrieved 15 February 2024 at https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html."},{"key":"19973_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, DAmico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Compr Canc Netw."},{"key":"19973_CR4","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer 2024. Retrieved 15 February 2024 at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"19973_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejso.2021.08.012","volume":"48","author":"M Choi","year":"2022","unstructured":"Choi M, Ishizawa S, Kraemer D, Sasson A, Feinberg E. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: a Markov decision analysis. Eur J Surg Oncol. 2022;48:403\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2021.08.012.","journal-title":"Eur J Surg Oncol."},{"key":"19973_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med."},{"key":"19973_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s40001-023-01400-3","volume":"28","author":"P Su","year":"2023","unstructured":"Su P, Jiang L, Zhang Y, et al. Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study. Eur J Med Res. 2023;28:409. https:\/\/doi.org\/10.1186\/s40001-023-01400-3.","journal-title":"Eur J Med Res."},{"key":"19973_CR8","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/jco.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313. https:\/\/doi.org\/10.1200\/jco.20.02914.","journal-title":"J Clin Oncol."},{"key":"19973_CR9","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JH, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol. 2024;42:2961\u20135. https:\/\/doi.org\/10.1200\/JCO.23.02167.","journal-title":"J Clin Oncol."},{"key":"19973_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3389\/fonc.2020.01149","volume":"10","author":"Q Chen","year":"2020","unstructured":"Chen Q, Liu Z, Zhong Q, et al. Clinical impact of delayed initiation of adjuvant chemotherapy among patients with stage II\/III gastric cancer: can we do better? Front Oncol. 2020;10:1149. https:\/\/doi.org\/10.3389\/fonc.2020.01149.","journal-title":"Front Oncol."},{"key":"19973_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jjco\/hyaa223","volume":"51","author":"H Tsujimoto","year":"2021","unstructured":"Tsujimoto H, Kouzu K, Sugasawa H, et al. Impact of postoperative infectious complications on adjuvant chemotherapy administration after gastrectomy for advanced gastric cancer. Jpn J Clin Oncol. 2021;51:379\u201386. https:\/\/doi.org\/10.1093\/jjco\/hyaa223.","journal-title":"Jpn J Clin Oncol."},{"key":"19973_CR12","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1245\/s10434-020-09403-8","volume":"28","author":"MR Ju","year":"2021","unstructured":"Ju MR, Karalis JD, Blackwell JM, et al. Inaccurate clinical stage is common for gastric adenocarcinoma and is associated with undertreatment and worse outcomes. Ann Surg Oncol. 2021;28:2831\u201343. https:\/\/doi.org\/10.1245\/s10434-020-09403-8.","journal-title":"Ann Surg Oncol."},{"key":"19973_CR13","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1245\/s10434-013-2901-1","volume":"20","author":"CC Lerro","year":"2013","unstructured":"Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the National Cancer Database with those in population-based central cancer registries. Ann Surg Oncol. 2013;20:1759\u201365. https:\/\/doi.org\/10.1245\/s10434-013-2901-1.","journal-title":"Ann Surg Oncol."},{"key":"19973_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research communications in statistics. Simul Comput. 2009;38:1228\u201334. https:\/\/doi.org\/10.1080\/03610910902859574.","journal-title":"Simul Comput."},{"key":"19973_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12874-022-01542-8","volume":"22","author":"A Elhakeem","year":"2022","unstructured":"Elhakeem A, Hughes RA, Tilling K, et al. Using linear and natural cubic splines, SITAR, and latent trajectory models to characterise nonlinear longitudinal growth trajectories in cohort studies. BMC Med Res Method. 2022;22:68. https:\/\/doi.org\/10.1186\/s12874-022-01542-8.","journal-title":"BMC Med Res Method."},{"key":"19973_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.surg.2017.09.021","volume":"163","author":"TB Tran","year":"2018","unstructured":"Tran TB, Worhunsky DJ, Squires MH, et al. Clinicopathologic score predicting lymph node metastasis in T1 gastric cancer. Surgery. 2018;163:889\u201393. https:\/\/doi.org\/10.1016\/j.surg.2017.09.021.","journal-title":"Surgery."},{"key":"19973_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12957-022-02596-0","volume":"20","author":"Y Chen","year":"2022","unstructured":"Chen Y, Jia Y, Peng Z, Wang G. The prognostic role of tumor size in stage T1 gastric cancer. World J Surg Oncol. 2022;20:135. https:\/\/doi.org\/10.1186\/s12957-022-02596-0.","journal-title":"World J Surg Oncol."},{"key":"19973_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1148\/radiology.181.2.1924784","volume":"181","author":"JF Botet","year":"1991","unstructured":"Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology. 1991;181:426\u201332. https:\/\/doi.org\/10.1148\/radiology.181.2.1924784.","journal-title":"Radiology."},{"key":"19973_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1245\/s10434-006-9037-5","volume":"14","author":"D Bentrem","year":"2007","unstructured":"Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14:1853\u20139. https:\/\/doi.org\/10.1245\/s10434-006-9037-5.","journal-title":"Ann Surg Oncol."},{"key":"19973_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1046\/j.1365-2168.2001.01725.x","volume":"88","author":"T Gotoda","year":"2001","unstructured":"Gotoda T, Sasako M, Ono H, Katai H, Sano T, Shimoda T. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg. 2001;88:444\u20139. https:\/\/doi.org\/10.1046\/j.1365-2168.2001.01725.x.","journal-title":"Br J Surg."},{"key":"19973_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jss.2019.02.037","volume":"240","author":"Y Liang","year":"2019","unstructured":"Liang Y, Liu L, Xie X, et al. Tumor size improves the accuracy of the prognostic prediction of lymph node-negative gastric cancer. J Surg Res. 2019;240:89\u201396. https:\/\/doi.org\/10.1016\/j.jss.2019.02.037.","journal-title":"J Surg Res."},{"key":"19973_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.amjsurg.2006.03.004","volume":"192","author":"H Saito","year":"2006","unstructured":"Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192:296\u2013300. https:\/\/doi.org\/10.1016\/j.amjsurg.2006.03.004.","journal-title":"Am J Surg."},{"key":"19973_CR23","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/1097-0142(20001001)89:7<1418::AID-CNCR2>3.0.CO;2-A","volume":"89","author":"Y Adachi","year":"2000","unstructured":"Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer. 2000;89:1418\u201324.","journal-title":"Cancer."},{"key":"19973_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1186\/s12885-018-4780-0","volume":"18","author":"F Feng","year":"2018","unstructured":"Feng F, Liu J, Wang F, Zheng G, Wang Q, Liu S, Zhang H. Prognostic value of differentiation status in gastric cancer. BMC Cancer. 2018;18:865. https:\/\/doi.org\/10.1186\/s12885-018-4780-0.","journal-title":"BMC Cancer."},{"key":"19973_CR25","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1007\/s00464-020-07532-5","volume":"35","author":"JN Chen","year":"2021","unstructured":"Chen JN, Wang QW, Zhang QW, Tang ZR, Li XB. Poorly differentiated is more significant than signet ring cell component for lymph node metastasis in mixed-type early gastric cancer: a retrospective study from a large-volume hospital. Surg Endosc. 2021;35:1558\u201365. https:\/\/doi.org\/10.1007\/s00464-020-07532-5.","journal-title":"Surg Endosc."},{"key":"19973_CR26","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1245\/s10434-013-3466-8","volume":"21","author":"ZM Bamboat","year":"2014","unstructured":"Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014;21:1678\u201385. https:\/\/doi.org\/10.1245\/s10434-013-3466-8.","journal-title":"Ann Surg Oncol."},{"key":"19973_CR27","doi-asserted-by":"publisher","first-page":"642468","DOI":"10.3389\/fsurg.2021.642468","volume":"8","author":"X Dong","year":"2021","unstructured":"Dong X, Sun G, Qu H, He Q, Hao Z. Prognostic significance of signet-ring cell components in patients with gastric carcinoma of different stages. Front Surg. 2021;8:642468. https:\/\/doi.org\/10.3389\/fsurg.2021.642468.","journal-title":"Front Surg."},{"issue":"10184","key":"19973_CR28","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet."},{"key":"19973_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, MATTERHORN Investigators, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med."},{"key":"19973_CR30","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1245\/s10434-024-15418-2","volume":"31","author":"F Abboretti","year":"2024","unstructured":"Abboretti F, Lambert C, Schafer M, Group AS, Surgery AF-FAo. Neoadjuvant chemotherapy does not improve survival in cT2N0M0 gastric adenocarcinoma patients: a multicenter propensity score analysis. Ann Surg Oncol. 2024;31:5273\u201382. https:\/\/doi.org\/10.1245\/s10434-024-15418-2.","journal-title":"Ann Surg Oncol."},{"key":"19973_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/jso.24894","volume":"117","author":"E Gabriel","year":"2018","unstructured":"Gabriel E, Attwood K, Narayanan S, Brady M, Nurkin S, Hochwald S, Kukar M. Does neoadjuvant\/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma? J Surg Oncol. 2018;117:659\u201370. https:\/\/doi.org\/10.1002\/jso.24894.","journal-title":"J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19973-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:52:52Z","timestamp":1789667572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19973-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["19973"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19973-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}